South Korean study links rapid diabetes progression to increased pancreatic cancer risk

A Seoul-based study reveals that newly diagnosed diabetes patients showing fast disease progression, such as early insulin requirement and treatment escalation, may indicate a higher risk of developing pancreatic cancer, highlighting potential markers for earlier detection.

A new South Korean study suggests that the way diabetes presents in its first months may help flag people at higher risk of pancreatic cancer, a disease that is often diagnosed late because it tends to cause few clear early symptoms. Researchers at Severance Hospital in Seoul said the strongest warning signs were a higher treatment burden at diagnosis and a rapid need to intensify therapy soon afterwards. The findings, published in Gut, add to earlier evidence that new-onset diabetes can sometimes be an early clue to an underlying pancreatic tumour.

The team analysed National Health Insurance Service data from 2002 to 2019, following more than 400,000 adults for up to 15 years. Among newly diagnosed type 2 diabetes patients aged 40 and over, those who needed medication, or insulin in particular, at the time of diagnosis faced a higher risk of later pancreatic cancer than people without diabetes. The pattern was even more striking when cancer was diagnosed within three years of the diabetes diagnosis, which supports the idea that rapidly worsening glucose control may sometimes reflect an already developing pancreatic cancer rather than diabetes alone.

The study also found that a quick escalation in treatment after diagnosis mattered. Patients whose therapy was stepped up within six months, including those who moved from tablets to insulin, had a substantially higher risk than those whose treatment stayed the same or eased. In one subgroup, the estimated risk rose sharply when insulin was introduced soon after initial oral treatment. The researchers said the absolute risk remained low, however, and stressed that diabetes by itself is not a reason to assume cancer.

The results fit with a series of recent population studies that have pointed in the same direction. A Danish nationwide cohort published in 2023 found that new-onset diabetes in adults aged 50 and older was linked with a higher risk of pancreatic cancer. Other studies from 2023 reported that new-onset diabetes may act as an early indicator of the disease, while broader research has suggested that sustained hyperglycaemia increases pancreatic cancer risk and that quitting smoking lowers it. Taken together, the evidence points to a more nuanced approach: not every person with diabetes needs cancer screening, but those with a sudden, severe or rapidly worsening presentation may warrant closer follow-up.